[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:cutaneous-melanoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":123,"states":124},"Cutaneous Melanoma",18,15,[8,16,23,29,36,42,49,55,61,67,73,79,85,91,97,103,110,116],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04697576","Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma",[12],"Phase 1","RECRUITING","2026-08-26T02:19:15.498463Z","2026-07-19T19:36:05.115146Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06743126","SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma",[20],"Phase 3","2026-08-26T02:16:03.788292Z","2026-07-05T05:32:16.693529Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06673095","Narrow Excision Versus Wide Excision for the Treatment of Adults With Invasive Cutaneous Melanoma, ICEMAN Trial",[],"2026-08-26T02:15:17.167444Z","2026-05-05T02:43:29.531334Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT06961006","A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012\u002FINTerpath-012)",[33],"Phase 2","2026-08-26T02:18:42.501841Z","2026-05-05T02:43:28.675895Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT06946225","ACTengine® IMA203 Combined With mRNA-4203",[12],"2026-08-26T02:15:29.632183Z","2026-05-05T02:43:26.949927Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":47,"content_modified":48},"NCT06194929","Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma",[46],"Phase 1\u002FPhase 2","2026-08-26T02:15:10.362237Z","2026-05-05T02:43:26.716817Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT07155317","Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial",[33],"2026-08-26T02:17:43.321968Z","2026-05-05T02:43:27.602103Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT06223659","EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers",[33],"2026-08-26T02:16:02.918558Z","2026-05-05T02:43:27.591625Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT03947385","Study of IDE196 in Patients With Solid Tumors Harboring GNAQ\u002F11 Mutations or PRKC Fusions",[46],"2026-08-26T02:17:05.997056Z","2026-05-05T02:43:26.921459Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT06330064","A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)",[33],"2026-08-26T02:18:11.042248Z","2026-05-05T02:43:29.734746Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT05669430","A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies",[46],"2026-08-26T02:17:23.750999Z","2026-05-05T02:43:28.900585Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT06961357","Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma",[46],"2026-08-26T02:15:04.877798Z","2026-05-05T02:43:28.848519Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT06090266","A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents",[46],"2026-08-26T02:15:03.757872Z","2026-05-05T02:43:27.247900Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT04792463","Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome",[],"2026-08-26T02:15:56.561131Z","2026-05-13T02:55:06.269987Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT03842943","Neoadjuvant Combination Immunotherapy for Stage III Melanoma",[33],"2026-08-26T02:17:21.315591Z","2026-05-05T02:43:27.477590Z",{"nct_id":104,"title":105,"phases":106,"status":107,"updated_at":108,"content_modified":109},"NCT07068074","A Randomized Phase III Study of Management of Treatment Naive Primary Melanoma in Elderly Patients",[20],"NOT_YET_RECRUITING","2026-08-26T02:18:34.622081Z","2026-05-05T02:43:28.541929Z",{"nct_id":111,"title":112,"phases":113,"status":107,"updated_at":114,"content_modified":115},"NCT07631325","Axelopran in Patients With Anti-PD-1 Refractory Metastatic or Locoregionally Unresectable Cutaneous Melanoma",[46],"2026-08-26T02:15:57.572488Z","2026-06-14T18:39:22.249840Z",{"nct_id":117,"title":118,"phases":119,"status":120,"updated_at":121,"content_modified":122},"NCT07259304","Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors",[],"ACTIVE_NOT_RECRUITING","2026-08-03T02:10:37.231905Z","2026-05-13T02:55:06.681744Z",[],[125,129,133,137,141,144,148,151,154,158,161,164,167,170],{"state":126,"count":127,"slug":128},"California",8,"california",{"state":130,"count":131,"slug":132},"Texas",7,"texas",{"state":134,"count":135,"slug":136},"Ohio",6,"ohio",{"state":138,"count":139,"slug":140},"New York",5,"new-york",{"state":142,"count":139,"slug":143},"Virginia","virginia",{"state":145,"count":146,"slug":147},"Michigan",4,"michigan",{"state":149,"count":146,"slug":150},"Pennsylvania","pennsylvania",{"state":152,"count":146,"slug":153},"Tennessee","tennessee",{"state":155,"count":156,"slug":157},"Colorado",3,"colorado",{"state":159,"count":156,"slug":160},"Florida","florida",{"state":162,"count":156,"slug":163},"Massachusetts","massachusetts",{"state":165,"count":156,"slug":166},"Oregon","oregon",{"state":168,"count":156,"slug":169},"Utah","utah",{"state":171,"count":156,"slug":172},"Washington","washington"]